Post-earnings recap
Reported
Fri, May 5, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CytomX Therapeutics reported a loss per share of $0.23, but the stock rose by 2.25% following the earnings announcement. The increase in stock price may reflect investor optimism despite the lack of revenue information and guidance. The market's reaction suggests that investors are willing to overlook the EPS miss, possibly anticipating future developments.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.